14029-71-1

Usage

Uses

Used in Pharmaceutical Research and Development:
1,3-Diethyl 2-[(pyridin-3-yl)amino]-methylidenepropanedioate is utilized as a chemical entity in pharmaceutical research and development for its potential pharmacological activity. 1,3-Diethyl 2-[(pyridin-3-yl)amino]-methylidenepropanedioate's unique structure, which includes a diethyl ester group and a pyridine ring connected to an amino-methylidene group, endows it with promising biological activities that are of interest in the field of drug discovery and design.
Used in Drug Discovery:
In the realm of drug discovery, 1,3-Diethyl 2-[(pyridin-3-yl)amino]-methylidenepropanedioate serves as a lead compound for the development of new pharmaceutical agents. Its potential medicinal properties make it a candidate for further investigation, with the aim of identifying and optimizing its therapeutic effects for various medical conditions.
Used in Medicinal Chemistry:
1,3-Diethyl 2-[(pyridin-3-yl)amino]-methylidenepropanedioate is employed in medicinal chemistry as a structural template for the design and synthesis of novel compounds with improved pharmacological profiles. Its unique features, such as the diethyl ester and pyridine ring, provide a foundation for the modification and optimization of its biological activities, enhancing its potential as a therapeutic agent.

Upstream product

• 462-08-8 pyridin-3-ylamine 
• 87-13-8 diethyl 2-ethoxymethylenemalonate 
• 1462-86-8 3-amino-pyridine-2-carboxylic acid 

Downstream Products

• 13801-51-9 4-hydroxy-1,5-naphthyridine-3-carboxylic acid ethyl ester 
• 83067-94-1 4-oxo-1,4-dihydro-[1,5]naphthyridin-3-yl carboxylic acid ethyl ester 
• 4901-93-3 3-carboxy-4-hydroxy-1,5-naphthyridine 
• 5423-54-1 4-hydroxy-1,5-naphthyridine 
• 1617540-19-8 ethyl 1-((4'-chlorobiphenyl-2-yl)methyl)-4-oxo-1,4-dihydro-1,5-naphthyridine-3-carboxylate 
• 1617540-17-6 1-((4'-chlorobiphenyl-2-yl)methyl)-4-oxo-1,4-dihydro-1,5-naphthyridine-3-carboxylic acid 
• 1617540-16-5 ethyl 1-(2-(4-chlorophenylthio)benzyl)-4-oxo-1,4-dihydro-1,5-naphthyridine-3-carboxylate 
• 1617540-14-3 1-(2-(4-chlorophenylthio)benzyl)-4-oxo-1,4-dihydro-1,5-naphthyridine-3-carboxylic acid 
• 83067-95-2 4-chloro-1,5-naphthyridine-3-carboxylic acid ethyl ester 
• 1345868-12-3 C₂₆H₂₂F₂N₄O₃ 
• 1279716-19-6 ethyl 4-oxo-1-{[4-(1H-pyrazol-1-yl)phenyl]methyl}-1,4-dihydro-1,5-naphthyridine-3-carboxylate 
• 1279716-02-7 2-(2-fluorophenyl)-5-{[4-(1H-pyrazoI-1-yI)phenyl]methyl}-2,5-dihydro-3H-pyrazolo[4,3-c]-1,5-naphthyridin-3-one 
• 1279716-21-0 5-{[4-(1H-pyrazol-1-yl)phenyl]methyl}-2,5-dihydro-3H-pyrazolo[4,3-c]-1,5-naphthyridin-3-one 
• 1279716-20-9 ethyl 1-{[4-(1H-pyrazol-1-yl)phenyl]methyl}-4-thioxo-1,4-dihydro-1,5-naphthyridine-3-carboxylate 

Relevant academic research and scientific papers

Pharmaceutical composition for promoting fracture healing, preparation method thereof and application thereof

The invention relates to the technical field of medicines and discloses a pharmaceutical composition for promoting the fracture healing. Structurally speaking, the active ingredient of the pharmaceutical composition has the following structure: (img file = 'DDA0001638481410000011. TIF' wi= '347' he= '319'/) The pharmaceutical composition is mainly used for preparing medicines for promoting fracture healing. As far as action is concern, that medicine has good therapeutic effect on osteoporotic fracture, obviously promotes fracture heal, reduces blood viscosity, and has important promoting effect on osteocyte growth.

NAPHTHYRIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE

The present invention relates to a compound having the general formula (V), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, codrug, cocrystal, prodrug, tautomer, racemate, enantiomer, or diastereomer or mixture thereof, which are useful in treating, ameloriating or preventing a viral disease. Furthermore, specific combination therapies are disclosed.

MACROCYCLIC DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES

The invention relates to compounds of formula (Φ) as further defined herein and to the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to the uses thereof. The compounds and salts of the present invention inhibit anaplastic lymphoma kinase (ALK) and/or EML4-ALK and are useful for treating or ameliorating abnormal cell proliferative disorders, such as cancer.

Platinum complexes of 4-hydoxy-1,5-naphthyridines as emitting dyes

4-Hydoxy-1,5-naphthyridines (HNt) are derivatives of 8-hydroxyquinolines, yet possess a wider HOMO and LUMO band gap than the latter. The cyclometalated complex of platinum(II) with Nt exists in a square planner geometry, and has a high tendency to aggregate in condensedmedia. Such a phenomenon was verified by examining its photo-luminescence spectra in different concentrations. In a dilute solution, it exhibits a yellow phosphorescence centered at 530∑555 nm, yet red-shifted to ∑660 nm in a concentrated solution or in the solid state. This series of compounds can be used as emitting dyes in light-emitting diodes (LED). The LED devices with a configuration ITO/NPB/dye (6%) in CBP/BCP/AlQ3 or TPBI/LiF/Al displayed a yellow to red color, where NPB, CBP, BCP, AlQ3 and TPBI denote 4,4′-bis[N-(1-naphthyl), Nphenylamino] biphenyl, 4,4′-bis(carbazol-9-yl)biphenyl, 2,9-dimethyl-4,7-diphenyl-1,10-phenanthroline, tris(8-hydoxyquinolinato) aluminium, and 2,2′,2′-(1,3,5-benzenetriyl)tris(1-phenyl-1H- benzimidazole), respectively. The maximal light intensity exceeds 2.6 × 104 cd/m2 with an external quantum efficiency up to 5.8%.

HETEROCYCLIC-FUSED PYRAZOLO[4,3-c]PYRIDIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention is directed to heterocyclic fused pyrazole [4,3-c] pyridine-3-one compounds of formula (I): which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, s

Synthesis and structure-activity relationship studies of dihydronaphthyridinediones as a novel structural class of potent and selective PDE7 inhibitors

The synthesis and SAR studies of a series of structurally novel inhibitors of PDE7 are discussed. The best compounds from the series display low nanomolar inhibitory activity and are selective versus other PDE isoenzymes.

Pharmacomodulations around the 4-oxo-1,4-dihydroquinoline-3-carboxamides, a class of potent CB2-selective cannabinoid receptor ligands: Consequences in receptor affinity and functionality

CB2 receptor selective ligands are becoming increasingly attractive drugs due to the potential role of this receptor in several physiopathological processes. Thus, the development of our previously described series of 4-oxo-1,4-dihydroquinoline-3-carboxamides was pursued with the aim to further characterize the structure-affinity and structure-functionality relationships of these derivatives. The influence of the side chain was investigated by synthesizing compounds bearing various carboxamido and keto substituents. On the other hand, the role of the quinoline central scaffold was studied by synthesizing several 6-, 7-, or 8-chloro-4-oxo-1,4-dihydroquinolines, as well as 4-oxo-1,4-dihydronaphthyridine and 4-oxo-1,4-dihydrocinnoline derivatives. The effect of these modifications on the affinity and functionality at the CB2 receptor was studied and allowed for the characterization of new selective CB2 receptor ligands.

HAMMICK CYCLIZATIONS STUDIES ON THE MECHANISM OF THE HAMMICK REACTION

Heating of 3-hydroxypicolinic acid with the acetylketene precursor 2,2,4-trimethyldioxin-4-one, ethyl acetoacetate or ethyl 2-cyclopentaneonecarboxylate leads via the 3-O-acylated 3-hydroxypicolinic acids, which cannot be isolated, and subsequent decarboxylation to the corresponding Hammick cyclization products in up to 25 percent yields besides 3-hydroxypyridine.In the case of 3-aminopicolinic acid the 3-(3-oxobutyrylamido)picolinic acid can be isolated but gives on heating only 3-aminopyridine and 3-(3-oxobutyrylamido)pyridine albeit none of the anticipated Hammick cyclization products.The Hammick cyclization reactions, side reactions and reaction mechanisms are discussed.

6-(D-2-[4-hydroxy-1,5-naphthyridine-3-carboxamido]-2-[4-hydroxyphenyl]acetamido)-2,2-dimethyl-3-(5-tetrazolyl)penam

6-(D-2-[4-Hydroxy-1,5-naphthyridine-3-carboxamido]-2-[4-hydroxyphenyl]acetamido-2,2-dimethyl-3-(5-tetrazolyl)penam and the salts thereof are valuable antibacterial agents, particularly for the control of bacterial infections in mammals, especially man.